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A 13-valent pneumococcal conjugate vaccine has been studied in adults aged ≥50 years to compare the
immune response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been
the standard of care over the past 30 years. The results demonstrate that adults, regardless of whether they are
naive or previously vaccinated with the polysaccharide vaccine, have an overall superior antibody response
when vaccinated with the conjugate vaccine compared with the pneumococcal polysaccharide vaccine. More
importantly, the nature of the response is indicative of a T-cell–dependent response that elicits immunologi-
cal memory and, therefore, primes the immune system for either natural exposure or subsequent booster
vaccination with either conjugate or polysaccharide vaccine. The conjugate vaccine, which has been successful
in reducing pneumococcal disease in children, now provides a new approach to preventing pneumococcal
disease, including community-acquired pneumonia, in adults.
INTRODUCTION
Capsular polysaccharide conjugate vaccines directed at
invasive bacteria have had a signiﬁcant impact on the
burden of disease in children since their introduction
over 2 decades ago [1]. The success of these vaccines
reﬂects their ability to induce a functional antibody
response directed at the bacterial capsule that is T-cell
dependent, resulting not only in a robust initial
response but also in the establishment of immunologi-
cal memory [2]. This memory is an important mech-
anism for protection upon exposure to the pathogen
and for renewing immunity with subsequent immu-
nizations [1]. Over the past decade, a 7-valent
pneumococcal conjugate vaccine (PCV7; pneumococ-
cal serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) has
been introduced into childhood vaccination programs
globally, resulting in a signiﬁcant reduction in both in-
vasive pneumococcal disease (IPD) and mucosal disease
(including community-acquired pneumonia [CAP] and
otitis media) [3].
However, in adults aged ≥50 years, the burden of
pneumococcal disease remains high. Recent estimates
suggest that in the United States, the annual burden is
as high as 30000 cases of IPD, 500000 cases of CAP,
and 25000 deaths [4]. Multivalent, pneumococcal-free
polysaccharide vaccines have been available for over 20
years [5].In the United States, a 23-valent pneumococcal
polysaccharidevaccine(PPSV23)hasbeenrecommended
for all adults aged ≥65 years, and over the past decade
the vaccination rate has been around 60% [6, 7]. Never-
theless, there has been little impact on disease caused by
the serotypes that are unique to that vaccine [8]. This
lack of impact is likely due to the T-cell–independent
nature of the immune response to free polysaccharides
that results in short-lived B-cell responses. In addition,
memory B cells are not produced in response to most
free polysaccharide vaccines and, in fact, may be de-
pleted postvaccination resulting in hyporesponsiveness
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thermore, PPSV23 efﬁcacy against CAP has been difﬁcult to
document [5, 9] and a recent Cochrane analysis concluded that
“the meta-analysis does not provide compelling evidence to
support the routine use of pneumococcal polysaccharide vaccine
to prevent all-cause pneumonia or mortality” [10].
THE RATIONALE FOR A PNEUMOCOCCAL
CONJUGATED POLYSACCHARIDE VACCINE
FOR ADULTS
A 13-valent pneumococcal conjugate vaccine (PCV13) was
developed and recently licensed for use in children [11].
PCV13 contains conjugates for pneumococcal serotypes 1, 3,
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Since intro-
duction, combined effectiveness against the 6 additional sero-
types (1, 3, 5, 6A, 7F, and 19A) in this vaccine has been
demonstrated for invasive disease [12, 13], and for carriage in
children with otitis media, including evidence of cross-protec-
tion against serotype 6C [14]. A number of immunogenicity
studies have been performed with PCVs in adults and have
generally concluded that PCV7 elicits a superior response in
adults when compared with PPSV23. These studies have been
recently summarized [9]. However, in Malawi, a randomized
controlled trial with PCV7 administered to adults infected
with human immunodeﬁciency virus (HIV) following hospi-
talization for IPD demonstrated a 74% reduction in IPD [15],
whereas a prior trial with PPSV23 in an HIV-positive popu-
lation in Uganda did not demonstrate protection [16].
As a result of the success of conjugated pneumococcal poly-
saccharide vaccines in children and the encouraging, but
limited, data from clinical studies with PCV7 in adults, we
sought to test the ability of PCV13 to induce a response in
adults that was quantitatively and qualitatively different from
that seen with PPSV23. The clinical program was designed to
show that PCV13 could induce a T-cell–dependent response
that could then be recalled or boosted by either natural
exposure or a subsequent vaccination, or both. Pivotal phase 3
clinical trials have been performed in 2 populations of
adults aged ≥50 years: those who were naive to previous
vaccination (Study 004) [17, 18] and those who had been pre-
viously vaccinated with PPSV23 but not within the past 5 years
(Study 3005) [19]. The results from these trials have recently
been presented and details will be submitted for publication in
the near future. The results are brieﬂy summarized here.
The design and objectives of the 2 pivotal trials in these popu-
l a t i o n sa r es h o w ni nF i g u r e s1 and 2. In both trials, adults were
randomized to receive either PCV13 or PPSV23, and the response
after a single dose was evaluated. The subjects were subsequently
administered a second immunization with one of the vaccines
either 1 year later (Study 3005) or 3–4 years later (Study 004).
The antipneumococcal immune responses were measured using a
functional opsonophagocytic activity (OPA) assay, and these
responses were generally concordant with the immunoglobulin
G responses. As OPA is known to be the mechanism of protec-
tion against pneumococcal disease [5], it isthe most appropriate
assay for comparing antibody responses elicited by vaccines as
well as for comparing the responses to various dosing regi-
mens. To compare groups, a geometric mean titer ratio was
determined; if the lower 95% conﬁdence interval of the ratio
was above 0.5 for serotypes in common, then the response was
considered similar or noninferior. If, however, the lower 95%
conﬁdence interval was above 1.0, then the response was con-
sidered to be statistically signiﬁcantly higher or superior.
RESPONSE TO PCV13 IN NAIVE ADULTS
Study 004 [17, 18] was conducted in 2 age cohorts who had
never received a pneumococcal vaccine previously: those aged
50–59 years and 60–64 years (Figure 1). At the time of enroll-
ment and randomization, subjects had very low OPA titers
near the lower limit of detection in the assay in both age
groups. At 1 month following the ﬁrst dose in those aged 60–
64 years (mean age, 62 years), the response to a single dose of
PCV13 was at least as good as the response to PPSV23 for all
of the serotypes (noninferior) and statistically signiﬁcantly
higher for 9 of the 13 serotypes. The overall superior response
to a single dose of PCV13 was seen consistently throughout
the clinical program. The response to a dose of PCV13 in
those aged 50–59 years (mean age, 54 years) was superior to
the response in the 60–64 years cohort for 9 of 13 serotypes,
indicating the importance of age as a factor in the immune
response. The fact that 2–4 µg of conjugate vaccine induced a
better response than 25µg of free polysaccharide also likely
reﬂects the different immune response pathway used by the
T-cell–dependent antigens in PCV13.
A subset of the study subjects returned for a second immu-
nization with either PCV13 or PPSV23 3–4 years (average, 3.7
years) after the initial dose of either PCV13 or PPSV23. Prior
to the second immunization, antibody levels had waned in all
groups. However, a second dose of PCV13 resulted in a renewed
immune response, reﬂecting the response seen after the ﬁrst
PCV13 administration for all of the serotypes and, important-
ly, was statistically signiﬁcantly higher for 6 of the 13 serotypes.
A similar result was achieved when PCV13 was followed 3–4
years later by a dose of PPSV23. In this case, the response was
statistically higher for 7 of the 13 serotypes. These data demon-
strate that PCV13 primed the immune system for a booster
response to subsequent vaccination with either vaccine.
This result was in stark contrast to the response seen when
subjects received 2 doses of PPSV23. In this case, the second
dose of PPSV23 elicited a response that was statistically
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vaccines when compared with the response after the ﬁrst dose
of PPSV23. Of note, the response in subjects given 2 doses of
PCV13 was signiﬁcantly higher for all 12 serotypes common
to both vaccines when compared with that seen for subjects
receiving 2 doses of PPSV23.
The blunted immune state illustrated by the lower response
to subsequent immunization, observed in Study 004 for
PPSV23, conﬁrms previous ﬁndings of other investigators [20].
Studies of group A and C meningococcal polysaccharide vac-
cines and repeated doses of PPSV23 in adults and children
have shown that a state of immune tolerance or hyporespon-
siveness can develop to repeated polysaccharide vaccine
antigen exposures [21]. The mechanism of hyporesponsiveness
has remained undeﬁned for many years, but recently, Bryn-
jolfsson and colleagues [22] demonstrated in an animal study
with meningococcal C polysaccharide that hyporesponsiveness
is caused by apoptosis of memory B cells. Figure 3 shows the
Figure 1. Design of a phase 3, randomized, modiﬁed double-blind, active-controlled, multicenter trial (Study 004) conducted in the United States in
subjects naive to 23-valent pneumococcal polysaccharide vaccine (PPSV23). Subjects aged 60–64 years were randomized to receive either 13-valent
pneumococcal conjugate vaccine (PCV13) or PPSV23 as a ﬁrst dose; subjects aged 50–59 years received PCV13 only as a ﬁrst dose. All groups received
a second vaccination with either PCV13 or PPSV23, 3–4 years after the ﬁrst dose. Opsonophagocytic activity was measured at the time of the ﬁrst
dose, 1 and 12 months after the ﬁrst dose, at the time of the second dose, and 1 month after the second dose. Abbreviations: PCV13, 13-valent
pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
Figure 2. Design of a phase 3, randomized, modiﬁed double-blind, active-controlled multicenter trial (Study 3005) conducted in the United States and
Sweden in healthy subjects aged at least 70 years who received a previous vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
at least 5 years before study enrollment. Subjects were randomized to receive either 13-valent pneumococcal conjugate vaccine (PCV13) or PPSV23 as a
ﬁrst dose, with both groups receiving a dose of PCV13 1 year after the ﬁrst dose. Opsonophagocytic activity was measured at the time of each dose
and 1 month after each dose. Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide
vaccine.
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illustrative of the sequences for the majority of serotypes. The
conjugate vaccine induces an immune response that is
superior to the free polysaccharide vaccine after the ﬁrst dose
but, more importantly, has primed the immune system for a
second dose of either vaccine. In contrast, the PPSV23 vaccine
inhibits the response to a second dose of the same vaccine,
and this was seen for all of the serotypes.
RESPONSE TO PCV13 IN ADULTS WHO HAD
PREVIOUSLY RECEIVED PPSV23
It was important to show that PCV13 could also prime the
immune system in individuals previously immunized with
PPSV23. Study 3005 [19] enrolled PPSV23 exposed individ-
uals (mean age, 77 years) to receive either PCV13 or PPSV23
again (Figure 2). The pattern of the immune response was es-
sentially the same as that seen in the PPSV23-naive adults
(Study 004), although the magnitude of the response was
somewhat lower in these older individuals. The response to
PCV13 was at least as good as the response to PPSV23 and
was statistically signiﬁcantly higher for 11 of the 13 serotypes.
Subjects were reimmunized 1 year later with PCV13,
regardless of whether they had received PCV13 or PPSV23
the previous year. Subjects who had previously received a dose
of PCV13 had a response that was at least noninferior to the
ﬁrst dose. In contrast, subjects who had received PPSV23 a
year previous had a signiﬁcantly reduced response to PCV13.
Although Study 004 in vaccine-naive adults showed that
PPSV23 blunted the response to a second dose of the same
vaccine, Study 3005 showed that PPSV23 also blunted the
response to a dose of the conjugate vaccine. Figure 4 shows
the pattern of responsiveness to serotype 1 as an example.
CONCLUSION
PCV13 is a new tool for meeting the signiﬁcant unmet medical
need to prevent pneumococcal disease in adults. It induces a T-
cell–dependent immune response in adults that can be recalled
or boosted by a subsequent dose of PCV13 or free polysacchar-
ide vaccine. The latter observation may be considered a surro-
gate for exposure to the polysaccharide during a “natural”
infection. Thus, by priming the immune system, PCV13 pro-
vides the potential to signiﬁcantly enhance and prolong immune
protection by response to either natural exposure or to booster
vaccination. The conjugate vaccine may also provide an
Figure 3. Functional immune responses for pneumococcal serotype 1 (geometric mean titer) in the pivotal noninferiority trial (Study 004) measured
pre- and postvaccination using a functional opsonophagocytic activity assay. Antibodies were determined before ﬁrst vaccination (pre-dose 1), 1 month
after vaccination (1 month post), and 12 months after ﬁrst vaccination (12 months post); and before the second vaccination 3–4 years later (pre-dose 2)
and 1 month after the second vaccination (post-dose 2). Abbreviations: GMT, geometric mean titer; OPA, opsonophagocytic activity; PCV13, 13-valent
pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.
262 ￿ CID 2012:55 (15 July) ￿ VACCINESimportant option for previously immunized adults in whom
revaccination with a polysaccharide is generally not
recommended.
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